IVUS

The Worldwide Intravascular Ultrasound Devices Industry is Expected to Reach $1 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 1, 2022
Medical Devices, Health, Stent, Atheroma, Coronary artery disease, Growth, Physician, Time, Prevalence, American College, Stenosis, COVID-19, Industry, Adoption, Angioplasty, PCI, ACC, Agent handling, Intravascular ultrasound, IVUS, Blood, Patient, Degenerative disease, CAGR, Hospital, Medical imaging, Marketing

The global intravascular ultrasound (IVUS) devices market is expected to grow from US$ 608.97 million in 2021 to $1,012.37 million by 2028; it is estimated to grow at a CAGR of 7.5% from 2021 to 2028.

Key Points: 
  • The global intravascular ultrasound (IVUS) devices market is expected to grow from US$ 608.97 million in 2021 to $1,012.37 million by 2028; it is estimated to grow at a CAGR of 7.5% from 2021 to 2028.
  • Due to the COVID-19 pandemic, the demand for intravascular ultrasound (IVUS) devices has increased.
  • The rising prevalence of cardiovascular diseases eventually boosts the growth of the intravascular ultrasound (IVUS) devices market.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Intravascular Ultrasound (IVUS) Devices Market.

Conavi Medical Plans for Strategic Expansion in U.S. Market

Retrieved on: 
Tuesday, February 15, 2022
Biotechnology, Medical Devices, Health, Radiology, Cardiology, Adoption, Food, MHLW, Health Canada, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, OCT, Ministry, IVUS, Research, Medical imaging, Health, Operation

Thomas Looby, chief executive officer, Conavi Medical, appointed in April of 2021 to focus on the companys strategic growth plans, has set the U.S. market as the companys near-term focus.

Key Points: 
  • Thomas Looby, chief executive officer, Conavi Medical, appointed in April of 2021 to focus on the companys strategic growth plans, has set the U.S. market as the companys near-term focus.
  • Loobys extensive background in leading medical device companies and developing global markets for cutting-edge technology bolsters the leadership team as they prepare for new milestones.
  • To efficiently execute this expansion, Robert Skidmore joined as vice president of Operations in October 2021 to scale up production to meet the expected demand.
  • Conavi Medical Inc., is a privately-held company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures.

Philips delivers Q4 sales of EUR 4.9 billion and income from continuing operations of EUR 139 million; Adjusted EBITA margin amounts to 13.1%, operating cash flow is EUR 720 million; good demand drives mid-single-digit order intake growth

Retrieved on: 
Monday, January 24, 2022
Spectral, Personal health record, Algorithm, Zhengzhou University, Science and technology in Asia, EUR, The First Affiliated Hospital of Wenzhou Medical University, Respironics, AI, Philips, Medical imaging, Personal, Technology, CDP, IVUS, COVID-19, ISO, Adoption, Climate change, Treatment, FDA, Hospital, Biotelemetry, Sonicare, Comparable, Hospital, patients, health, territories, Stiftung Warentest, Diagnosis, Growth, Income, Share repurchase, Solution, Health, Program, CT, Workflow, Machine learning, Acquisition, First Affiliated Hospital of Xinjiang Medical University, VOC, Multan Institute of Cardiology, Bed, ECG, Â, DreamSTATE, Infection, Film, Commercial property, Pharmaceutical industry, Fine chemical, Medical device, Cassette tape, Adjustment, Ultrasound, Group

This further builds on the high-single-digit Group comparable order intake growth in 2020, resulting in an all-time-high order book.

Key Points: 
  • This further builds on the high-single-digit Group comparable order intake growth in 2020, resulting in an all-time-high order book.
  • Based on good customer demand and our growing order book, we expect to resume our growth and margin expansion trajectory in the course of 2022.
  • For the Group, we target 3-5% comparable sales growth and a 40-90 basis-points improvement in Adjusted EBITA margin.
  • For the full year, the Diagnosis & Treatment businesses recorded 8% comparable sales growth and an Adjusted EBITA margin of 12.4%.

Philips to further expand its image-guided therapy devices portfolio through acquisition of Vesper Medical

Retrieved on: 
Tuesday, December 14, 2021
Vesper, AEX, Physician, Tack, Diagnosis, Growth, NYSE, Acquisition, DVD, CEO, Patient, Peripheral artery disease, PAD, PHG, IVUS, Philips, Senior, Technology, Pharmaceutical industry, Medical imaging

Vesper Medical will further expand Philips portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease.

Key Points: 
  • Vesper Medical will further expand Philips portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease.
  • Complementing Philips strong IVUS offering in venous imaging, Vesper Medical will add a venous stenting solution to address the root cause of chronic deep venous disease (DVD).
  • The acquisition of Vesper Medical is another step in our objective to innovate patient treatment with more sophisticated technology and expand our growth in the vascular therapy space, said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips.
  • Upon completion of the transaction, Vesper Medical and approximately 20 of its employees will become part of Philips Image-Guided Therapy business.

Conavi Medical Enters into Funding Agreements for Over $20 Million to Support Commercialization of its Innovative Intravascular Image Guidance Technology

Retrieved on: 
Wednesday, December 15, 2021
Science, Cardiology, Biotechnology, Research, Health, FDA, Medical Devices, Clinical Trials, Food, Health Canada, Company, Growth, Hospital, Nature, Adoption, Infarction, PCI, Angioplasty, OCT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Â, Patient, Coronary artery disease, IVUS, Ministry, TCT, NewYork-Presbyterian Hospital, MHLW, Angina, Pharmaceutical industry, Medical imaging, Health

Conavi Medical Inc. ( www.conavi.com ), a leader of hybrid imaging guidance for common minimally invasive heart procedures, has entered into agreements for over $20 million in funding to support commercialization and growth as it prepares its innovative Novasight Hybrid System for market.

Key Points: 
  • Conavi Medical Inc. ( www.conavi.com ), a leader of hybrid imaging guidance for common minimally invasive heart procedures, has entered into agreements for over $20 million in funding to support commercialization and growth as it prepares its innovative Novasight Hybrid System for market.
  • Conavi Medical is leading the way with its Novasight Hybrid System as a new imaging platform for use by interventional cardiologists during common minimally invasive heart procedures.
  • This patented technology is the first and only clinical system that enables simultaneous and co-registered imaging of coronary arteries with both intravascular ultrasound (IVUS) and optical coherence tomography (OCT).
  • This transformational funding is a testament to the potential the Novasight Hybrid System has on a global scale.

Intravascular ultrasound (IVUS) linked with improved health outcomes in largest-ever real-world analysis of lower extremity peripheral vascular interventions

Retrieved on: 
Monday, November 8, 2021
Health, Mortality, TCT, Amputation, Stenosis, Outcomes research, Centers for Medicare & Medicaid Services, CMS, Medicare, Moyamoya disease, MD, PAD, Chronic limb threatening ischemia, Boston Scientific, Ageing, Technology, Philips, Harvard Medical School, Peripheral artery disease, Senior, Beth Israel Deaconess Medical Center, USA, Interventional cardiology, Software, Fatigue, Decision-making, Plaque, IVUS, Leg, Cohort study, Research, Smith Center, PHG, Solution, CLI, Hospital, Foot, Center, NYSE, Death, CVD, Physician, Review, Assistant, Vascular disease, Patient, VIVA, Risk, Literature, AEX, Meat, Birth control, Pharmaceutical industry, Medical imaging

Numerous prospective studies have already shown the benefit of IVUS guidance in peripheral vascular interventions, making it a gold-standard imaging modality for this application.

Key Points: 
  • Numerous prospective studies have already shown the benefit of IVUS guidance in peripheral vascular interventions, making it a gold-standard imaging modality for this application.
  • The results of this large-scale study demonstrate favorable long-term outcomes in peripheral vascular interventions when IVUS is used, said Eric Secemsky, MD.
  • Peripheral artery disease (PAD): a 32% reduction in major adverse limb events, including amputations, during lower extremity arterial interventions
    The study looked at Medicare beneficiaries aged 65 years or older who underwent lower extremity arterial interventions between January 1, 2016, and December 31, 2019.
  • Peripheral artery disease develops when plaque builds up in the vessel wall and reduces blood flow to the limbs, most commonly the legs.

HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE Trial

Retrieved on: 
Thursday, October 14, 2021
Death, CT, Technology, Degenerative disease, Diagnosis, Plaque, Silicon, Acute coronary syndrome, Heart, CCTA, 3D, Mount Sinai Hospital, Man, Rupture, Computational fluid dynamics, Multicenter Automatic Defibrillator Implantation Trial, MSA, Physician, IVUS, FACC, Algorithm, Woman, Interventional cardiology, Coronary artery disease, Intelligence, Trial of the century, Physiology, Patient, CAD, GLOBE, Muscle tissue, Anatomy, Kindai University, Moyamoya disease, Safety, CTA, DO, Principal, Deep learning, Cone Health, Mechanism, Analyse, Medical imaging

It is clear, however, that coronary plaque is the driving force behind understanding a patients risk of having a heart attack, said Dr. Meckel, lead Principal Investigator for REVEALPLAQUE at Bryan Heart.

Key Points: 
  • It is clear, however, that coronary plaque is the driving force behind understanding a patients risk of having a heart attack, said Dr. Meckel, lead Principal Investigator for REVEALPLAQUE at Bryan Heart.
  • To be able to accurately and non-invasively understand a patients plaque burden would be game changing in physicians abilities to save a patients life from a heart attack.
  • The REVEALPLAQUE trial is planned to enroll 250 patients with stable coronary artery disease from approximately 15 sites across the U.S. and Japan.
  • The HeartFlow FFRct Analysis is commercially available in the United States, UK, Canada, Europe and Japan.

Clinical experts establish first-ever global consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease interventions

Retrieved on: 
Tuesday, October 5, 2021
Philips, Harvard Medical School, Assistant, VIVA, Diagnosis, Health, Solution, Moyamoya disease, Software, Patient, Beth Israel Deaconess Medical Center, Physician, MD, Senior, Decision-making, IVUS, Gaps, PHG, AEX, NYSE, Interventional cardiology, Medical imaging, Medical device, Medicine

Future efforts need to focus on improving IVUS implementation into clinical practice and streamlining procedural workflow to help improve our patient outcomes.

Key Points: 
  • Future efforts need to focus on improving IVUS implementation into clinical practice and streamlining procedural workflow to help improve our patient outcomes.
  • As part of Philips peripheral vascular portfolio, IVUS provides the visualization and guidance essential for the optimal diagnosis and treatment of patients.
  • The new appropriate-use expert consensus may help establish global standards of care to adopt into guidelines and improve quality care in PVD.
  • They conducted a systematic and comprehensive review of key clinical IVUS scenarios and decision-making processes before voting as world experts in the field.

Dr. Paul Gagne Launches Vascular Care Connecticut to Deliver Patient-Centered Care to Darien

Retrieved on: 
Monday, September 20, 2021
Managed Care, General Health, Health, Surgery, Society for Vascular Surgery, Mouth ulcer, NYU, Compliance, Diagnosis, Patient, Health, Varicose veins, IVUS, FACS, Method, Environment, Vascular disease, New York University Grossman School of Medicine, RVT, Journal, Â, DVT, Peripheral artery disease, Safety, Venography, U.S. Navy Diving Manual, Private practice, Blood vessel, Society, Aortic aneurysm, Dentistry, Medical imaging

By augmenting the local hospital systems with specialized outpatient care, vascular centers such as ours can play a vital role in optimizing patient care locally, said Dr. Gagne.

Key Points: 
  • By augmenting the local hospital systems with specialized outpatient care, vascular centers such as ours can play a vital role in optimizing patient care locally, said Dr. Gagne.
  • Vascular Care Connecticut is dedicated to being on the cutting edge of innovation and new technologies for vascular disease and providing patients the care they need in a convenient and uncomplicated environment.
  • Vascular Care Connecticut is committed to the prevention, diagnosis, and treatment of vascular disease.
  • Vascular Care Connecticut brings together decades of experience to offer unparalleled care in Connecticut.

Global Intravascular Ultrasound Market Insights, Competitive Landscape and Market Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 15, 2021
Medical Devices, Health, IVUS, Research, Pet, Retail

What was the IVUS market share (%) distribution in 2018 and how it will look like in 2026?

Key Points: 
  • What was the IVUS market share (%) distribution in 2018 and how it will look like in 2026?
  • What will be the IVUS market growth till 2026 and what will be the resultant market size in the year 2026?
  • How will the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • What are the IVUS available in the market, their product description, regulatory milestones, product development activities, research and development activities etc.?